CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Baseline characteristics of participants enrolled in the empagliflozin cardiovascular outcome trial (EMPA-REG OUTCOME™) in patients with type 2 diabetes
DOI 10.1055/s-0034-1374995
Bibliografische Angaben
Nachweis in CareLit
Autor:innenB Zinman, S Inzucchi, J Lachin, C Wanner, R Ferrari, D Fitchett, E Bluhmki, J Kempthorne-Rawson, J Newman, OE Johansen, HJ Woerle, UC Broedl
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe05/2014
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background, material and methods: The EMPA-REG OUTCOME™ trial (NCT01131676) will investigate the effect of the sodium glucose cotransporter 2 inhibitor empagliflozin 10 mg or 25 mg od compared with placebo, upon a background of optimal standard of care, on cardiovascular (CV) outcomes in patients with type 2 diabetes mellitus (T2DM) at increased CV risk. The study is a double-blind, double-dummy and event-driven (69…
Zitieren
Zitierempfehlung
B Zinman, S Inzucchi, J Lachin, C Wanner, R Ferrari, D Fitchett, E Bluhmki, J Kempthorne-Rawson, J Newman, OE Johansen, HJ Woerle, UC Broedl (2014) Baseline characteristics of participants enrolled in the empagliflozin cardiovascular outcome trial (EMPA-REG OUTCOME™) in patients with type 2 diabetes. Diabetologie und Stoffwechsel (05). https://doi.org/10.1055/s-0034-1374995
Mit CareLit weiterarbeiten